Viewing Study NCT04994860


Ignite Creation Date: 2025-12-25 @ 2:04 AM
Ignite Modification Date: 2025-12-26 @ 4:42 AM
Study NCT ID: NCT04994860
Status: COMPLETED
Last Update Posted: 2021-08-06
First Post: 2021-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
Sponsor: Bial - Portela C S.A.
Organization:

Study Overview

Official Title: An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil in Healthy Subjects Under Fasting Conditions
Status: COMPLETED
Status Verified Date: 2021-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is:

* To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil.
* To assess the effect of sildenafil on the PK of BIA 5-1058.
Detailed Description: This study was an open label, three period, fixed sequence study in healthy male and female subjects performed under fasting conditions at a single study center.

The study comprised:

* Screening during Days -28 to -2 (both inclusive).
* Three treatment periods separated by a washout period of at least 10 days.

Duration of Treatment:

The duration of participation for each subject was approximately 2 months and 3 weeks (including the screening period).

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2017-000224-99 EUDRACT_NUMBER None View